New Directions in the Management of Advanced Prostate Cancer

[摘要] Approximately 70 years ago, Huggins and Hodges1 reported the benefits of androgen-deprivation therapy for advanced prostate cancer. The dramatic palliation associated with androgen deprivation did not require randomized, double-blind, placebo-controlled trials to convince urologists of their clinical utility. Since that time, androgen-deprivation therapy has continued to represent the first-line treatment for advanced prostate cancer. We have seen the development of different ways to achieve androgen deprivation that are more convenient and better tolerated but no better at increasing survival.

[学科分类] 基础医学